Paola Francica
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Paola Francica has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
Martín González-Fernández
3 shared publicationsErik Vassella
Institute of Tissue Medicine and Pathology, University of Bern, Bern, 3008 Switzerland
2 shared publicationsEwa Gogola
Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
2 shared publicationsIsmar Klebic
Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, Bern, Switzerland
2 shared publicationsLea Lingg
Department for BioMedical Research, University of Bern, Bern, 3008 Switzerland
2 shared publicationsMerve Mutlu
Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, Bern, Switzerland
2 shared publications
Latest Publications
- Open Access
- 7 August 2026
- Published by Springer Nature in Research Square
Targeting the LIPH-CD36 axis potentiates CDK4/6 inhibition in ER+ breast cancer
ER+/HER2 − breast cancer is commonly treated with endocrine therapy combined with CDK4/6 inhibitors (CDK4/6i), including palbociclib, ribociclib, and abemaciclib. Although these combinations have improved clinical outcome, resistance remains frequent, highlighting the need to identify vulnerabilities that enhance CDK4/6i response. To uncover metabolic dependencies associated with CDK4/6i sensitivity, we performed an unbiased loss-of-function screen targeting ∼2,800 metabolic genes. This identified lipase H (LIPH), a phosphatidic acid-selective phospholipase A1 that generates lysophosphatidic acid (LPA), as a candidate vulnerability in palbociclib-treated ER+/HER2- breast cancer cells. LIPH depletion reduced LPA levels and sensitized multiple ER+ models to palbociclib, ribociclib, and abemaciclib. Mechanistically, LIPH-derived LPA activated LPAR2-dependent AMPK/p38 signaling, sustaining CD36 expression. CD36 regulated cyclin D1 levels and cell-cycle progression, while LIPH or CD36 depletion reduced cyclin D1, induced G0/G1 accumulation, and enhanced CDK4/6i sensitivity. Conversely, exogenous LPA restored CD36 and cyclin D1 expression in LIPH-silenced cells. Genetic or pharmacological CD36 targeting potentiated CDK4/6i efficacy in endocrine-sensitive and therapy-resistant ER+ models, as well as in patient-derived organoids. Clinically, high LIPH/CD36 scores were associated with poor response to CDK4/6i-based therapy, while elevated LIPH, CD36, or combined LIPH/LPAR2/CD36 expression correlated with worse outcome in ER+/HER2 − breast cancer cohorts. Together, our findings identify the LIPH–LPA–LPAR2–CD36–cyclin D1 axis as a lipid-signaling vulnerability that modulates CDK4/6i response and propose LIPH and CD36 as candidate therapeutic targets and biomarkers in ER+/HER2- breast cancer.
- 7 August 2026
- Published by Springer Nature in Research Square
Open AccessTargeting the LIPH-CD36 axis potentiates CDK4/6 inhibition in ER+ breast cancer
ER+/HER2 − breast cancer is commonly treated with endocrine therapy combined with CDK4/6 inhibitors (CDK4/6i), including palbociclib, ribociclib, and abemaciclib. Although these combinations have improved clinical outcome, resistance remains frequent, highlighting the need to identify vulnerabilities that enhance CDK4/6i response. To uncover metabolic dependencies associated with CDK4/6i sensitivity, we performed an unbiased loss-of-function screen targeting ∼2,800 metabolic genes. This identified lipase H (LIPH), a phosphatidic acid-selective phospholipase A1 that generates lysophosphatidic acid (LPA), as a candidate vulnerability in palbociclib-treated ER+/HER2- breast cancer cells. LIPH depletion reduced LPA levels and sensitized multiple ER+ models to palbociclib, ribociclib, and abemaciclib. Mechanistically, LIPH-derived LPA activated LPAR2-dependent AMPK/p38 signaling, sustaining CD36 expression. CD36 regulated cyclin D1 levels and cell-cycle progression, while LIPH or CD36 depletion reduced cyclin D1, induced G0/G1 accumulation, and enhanced CDK4/6i sensitivity. Conversely, exogenous LPA restored CD36 and cyclin D1 expression in LIPH-silenced cells. Genetic or pharmacological CD36 targeting potentiated CDK4/6i efficacy in endocrine-sensitive and therapy-resistant ER+ models, as well as in patient-derived organoids. Clinically, high LIPH/CD36 scores were associated with poor response to CDK4/6i-based therapy, while elevated LIPH, CD36, or combined LIPH/LPAR2/CD36 expression correlated with worse outcome in ER+/HER2 − breast cancer cohorts. Together, our findings identify the LIPH–LPA–LPAR2–CD36–cyclin D1 axis as a lipid-signaling vulnerability that modulates CDK4/6i response and propose LIPH and CD36 as candidate therapeutic targets and biomarkers in ER+/HER2- breast cancer.
- Open Access
Aurora kinase A is a synthetic lethal target in FANCA-deficient cancers
Loss-of-function genomic alterations in FANCA occur across multiple cancer types, yet no molecularly tailored therapies have successfully exploited this potential vulnerability. Using complementary unbiased approaches, including a genome-wide CRISPR/Cas9 loss-of-function screen and a high-throughput drug screen in isogenic cancer cell-based models, we identified Aurora kinase A (AURKA) as a reproducible synthetic lethal target of FANCA-deficient cancers. Inhibition of AURKA induced chromosomal instability, micronucleation, and early G2/M arrest selectively in FANCA-deficient cells, consistent with an increased reliance on mitotic checkpoint control. Mechanistically, FANCA deficiency is associated with an elevated AURKA expression at both the transcriptomic and protein levels, and with an upregulation of mitotic spindle and G2/M checkpoint gene signatures. Analysis of large-scale cancer genomics datasets, including over 650,000 clinically sequenced tumors, confirms that FANCA is the most frequently altered Fanconi anemia pathway gene across cancers, and that Fanconi anemia–defective tumors exhibit an increased tumor mutational burden and genomic instability. Collectively, our findings point to AURKA inhibition as a promising precision treatment strategy in FANCA-deficient cancers and provide a rationale to further explore this strategy in the clinic.
Open AccessAurora kinase A is a synthetic lethal target in FANCA-deficient cancers
Loss-of-function genomic alterations in FANCA occur across multiple cancer types, yet no molecularly tailored therapies have successfully exploited this potential vulnerability. Using complementary unbiased approaches, including a genome-wide CRISPR/Cas9 loss-of-function screen and a high-throughput drug screen in isogenic cancer cell-based models, we identified Aurora kinase A (AURKA) as a reproducible synthetic lethal target of FANCA-deficient cancers. Inhibition of AURKA induced chromosomal instability, micronucleation, and early G2/M arrest selectively in FANCA-deficient cells, consistent with an increased reliance on mitotic checkpoint control. Mechanistically, FANCA deficiency is associated with an elevated AURKA expression at both the transcriptomic and protein levels, and with an upregulation of mitotic spindle and G2/M checkpoint gene signatures. Analysis of large-scale cancer genomics datasets, including over 650,000 clinically sequenced tumors, confirms that FANCA is the most frequently altered Fanconi anemia pathway gene across cancers, and that Fanconi anemia–defective tumors exhibit an increased tumor mutational burden and genomic instability. Collectively, our findings point to AURKA inhibition as a promising precision treatment strategy in FANCA-deficient cancers and provide a rationale to further explore this strategy in the clinic.
- Open Access
- 17 December 2025
- Published by Springer Nature in Oncogene
- Vol. 45 (4) , 491-504
MDC1 counteracts replication fork reversal and mediates chemosensitivity in BRCA1/2-deficient tumors
MDC1 is a key protein in DNA damage signaling. When DNA double-strand breaks (DSBs) occur, MDC1 localizes to the sites of DNA damage to promote the recruitment of other factors, including the 53BP1-mediated DSB repair pathway. By studying mechanisms of poly (ADP-ribose) polymerase inhibitor (PARPi) resistance in BRCA2; p53-deficient mouse mammary tumors, we identified a thus far unknown role of MDC1 in replication fork biology. Our results show that MDC1 localizes at active replication forks during normal DNA replication and regulates replication fork progression. It suppresses spontaneous fork reversal and regulates fork nucleolytic processing thereby promoting sensitivity to PARPi and cisplatin. In this way, MDC1 loss improves DNA damage tolerance and causes chemoresistance in BRCA1/2-deficient cells. We demonstrate that limiting MRE11 activity abolishes the reduced fork speed while MRE11 inhibition/depletion overcomes PARPi resistance in these cells. Overall, our data provides new insights into the role of MDC1 in replication fork progression that mediates PARPi- and cisplatin-induced DNA damage, in addition to its role in DSB repair.
- 17 December 2025
- Published by Springer Nature in Oncogene
- Vol. 45 (4) , 491-504
Open AccessMDC1 counteracts replication fork reversal and mediates chemosensitivity in BRCA1/2-deficient tumors
MDC1 is a key protein in DNA damage signaling. When DNA double-strand breaks (DSBs) occur, MDC1 localizes to the sites of DNA damage to promote the recruitment of other factors, including the 53BP1-mediated DSB repair pathway. By studying mechanisms of poly (ADP-ribose) polymerase inhibitor (PARPi) resistance in BRCA2; p53-deficient mouse mammary tumors, we identified a thus far unknown role of MDC1 in replication fork biology. Our results show that MDC1 localizes at active replication forks during normal DNA replication and regulates replication fork progression. It suppresses spontaneous fork reversal and regulates fork nucleolytic processing thereby promoting sensitivity to PARPi and cisplatin. In this way, MDC1 loss improves DNA damage tolerance and causes chemoresistance in BRCA1/2-deficient cells. We demonstrate that limiting MRE11 activity abolishes the reduced fork speed while MRE11 inhibition/depletion overcomes PARPi resistance in these cells. Overall, our data provides new insights into the role of MDC1 in replication fork progression that mediates PARPi- and cisplatin-induced DNA damage, in addition to its role in DSB repair.
- Open Access
TAOK1 regulates chemo- and radiosensitivity in BRCA1/2-deficient tumors
BRCA1/2-deficient cells are hypersensitive to replication stress- and DNA-damage-inducing agents such as poly(ADP-ribose) polymerase inhibitors (PARPi), platinum drugs, and ionizing radiation (IR), largely due to impaired homologous recombination repair and replication fork (RF) protection. The precise mechanisms underlying RF vulnerability in the absence of BRCA1/2 remain incompletely understood, however. Here, we identify Thousand And One Amino Acid Kinase 1 (TAOK1) as a novel regulator of RF dynamics that sensitizes BRCA1/2-deficient cells to both PARPi and IR. Unlike established DNA repair factors, such as PARG or the 53BP1-RIF1-shieldin-CST pathway, which mediate PARPi sensitivity while protecting cells against IR, TAOK1 promotes RF degradation and suppresses post-replicative damage repair. TAOK1 depletion stabilizes RFs and reduces replication-associated DNA damage in BRCA1/2-deficient cells, thereby conferring therapy resistance. Interestingly, we found that TAOK1 functions in RF regulation to be independent of its kinase activity. Instead, it interacts with PCNA and regulates ISG15 levels and thereby affects RF stability. Our findings reveal TAOK1 as a non-canonical mediator of therapy sensitivity in BRCA1/2-deficient tumors. Teaser: TAOK1 controls replication fork stability through PCNA and ISG15, affecting therapy response in BRCA1/2-deficient cancers.
Open AccessTAOK1 regulates chemo- and radiosensitivity in BRCA1/2-deficient tumors
BRCA1/2-deficient cells are hypersensitive to replication stress- and DNA-damage-inducing agents such as poly(ADP-ribose) polymerase inhibitors (PARPi), platinum drugs, and ionizing radiation (IR), largely due to impaired homologous recombination repair and replication fork (RF) protection. The precise mechanisms underlying RF vulnerability in the absence of BRCA1/2 remain incompletely understood, however. Here, we identify Thousand And One Amino Acid Kinase 1 (TAOK1) as a novel regulator of RF dynamics that sensitizes BRCA1/2-deficient cells to both PARPi and IR. Unlike established DNA repair factors, such as PARG or the 53BP1-RIF1-shieldin-CST pathway, which mediate PARPi sensitivity while protecting cells against IR, TAOK1 promotes RF degradation and suppresses post-replicative damage repair. TAOK1 depletion stabilizes RFs and reduces replication-associated DNA damage in BRCA1/2-deficient cells, thereby conferring therapy resistance. Interestingly, we found that TAOK1 functions in RF regulation to be independent of its kinase activity. Instead, it interacts with PCNA and regulates ISG15 levels and thereby affects RF stability. Our findings reveal TAOK1 as a non-canonical mediator of therapy sensitivity in BRCA1/2-deficient tumors. Teaser: TAOK1 controls replication fork stability through PCNA and ISG15, affecting therapy response in BRCA1/2-deficient cancers.
- Open Access
- 1 November 2013
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 12 (11) , 2415-2424
The Novel ATP-Competitive Inhibitor of the MET Hepatocyte Growth Factor Receptor EMD1214063 Displays Inhibitory Activity against Selected MET-Mutated Variants
The receptor tyrosine kinase MET is a prime target in clinical oncology due to its aberrant activation and involvement in the pathogenesis of a broad spectrum of malignancies. Similar to other targeted kinases, primary and secondary mutations seem to represent an important resistance mechanism to MET inhibitors. Here, we report the biologic activity of a novel MET inhibitor, EMD1214063, on cells that ectopically express the mutated MET variants M1268T, Y1248H, H1112Y, L1213V, H1112L, V1110I, V1206L, and V1238I. Our results show a dose-dependent decrease in MET autophosphorylation in response to EMD1214063 in five of the eight cell lines (IC50 2–43 nmol/L). Blockade of MET by EMD1214063 was accompanied by a reduced activation of downstream effectors in cells expressing EMD1214063-sensitive mutants. In all sensitive mutant-expressing lines, EMD1214063 altered cell-cycle distribution, primarily with an increase in G1 phase. EMD1214063 strongly influenced MET-driven biologic functions, such as cellular morphology, MET-dependent cell motility, and anchorage-independent growth. To assess the in vivo efficacy of EMD1214063, we used a xenograft tumor model in immunocompromised mice bearing NIH3T3 cells expressing sensitive and resistant MET-mutated variants. Animals were randomized for the treatment with EMD1214063 (50 mg/kg/d) or vehicle only. Remarkably, five days of EMD1214063 treatment resulted in a complete regression of the sensitive H1112L-derived tumors, whereas tumor growth remained unaffected in mice with L1213V tumors and in vehicle-treated animals. Collectively, the current data identifies EMD1214063 as a potent MET small-molecule inhibitor with selective activity towards mutated MET variants. Mol Cancer Ther; 12(11); 2415–24. ©2013 AACR.
- 1 November 2013
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 12 (11) , 2415-2424
Open AccessThe Novel ATP-Competitive Inhibitor of the MET Hepatocyte Growth Factor Receptor EMD1214063 Displays Inhibitory Activity against Selected MET-Mutated Variants
The receptor tyrosine kinase MET is a prime target in clinical oncology due to its aberrant activation and involvement in the pathogenesis of a broad spectrum of malignancies. Similar to other targeted kinases, primary and secondary mutations seem to represent an important resistance mechanism to MET inhibitors. Here, we report the biologic activity of a novel MET inhibitor, EMD1214063, on cells that ectopically express the mutated MET variants M1268T, Y1248H, H1112Y, L1213V, H1112L, V1110I, V1206L, and V1238I. Our results show a dose-dependent decrease in MET autophosphorylation in response to EMD1214063 in five of the eight cell lines (IC50 2–43 nmol/L). Blockade of MET by EMD1214063 was accompanied by a reduced activation of downstream effectors in cells expressing EMD1214063-sensitive mutants. In all sensitive mutant-expressing lines, EMD1214063 altered cell-cycle distribution, primarily with an increase in G1 phase. EMD1214063 strongly influenced MET-driven biologic functions, such as cellular morphology, MET-dependent cell motility, and anchorage-independent growth. To assess the in vivo efficacy of EMD1214063, we used a xenograft tumor model in immunocompromised mice bearing NIH3T3 cells expressing sensitive and resistant MET-mutated variants. Animals were randomized for the treatment with EMD1214063 (50 mg/kg/d) or vehicle only. Remarkably, five days of EMD1214063 treatment resulted in a complete regression of the sensitive H1112L-derived tumors, whereas tumor growth remained unaffected in mice with L1213V tumors and in vehicle-treated animals. Collectively, the current data identifies EMD1214063 as a potent MET small-molecule inhibitor with selective activity towards mutated MET variants. Mol Cancer Ther; 12(11); 2415–24. ©2013 AACR.